What is claimed is:

1. A crystalline solid of carvedilol or a solvate thereof characterized by data selected from the group consisting of a PXRD pattern with peaks at about 6.5, 7.3, 16.0, and 30.5 ± 0.2 degrees two-theta, a DSC thermogram with endothermic peaks at about 74° C and 112° C, and a FTIR spectrum with peaks at about 613, 740, 994, 1125, 1228, 1257, 1441, 1508, 1737, 2840, 3281, 3389, and 3470 cm^{-1}.
2. The carvedilol of claim **1** characterized by PXRD peaks at about 6.5, 7.3, 16.0, and 30.5 ± 0.2 degrees two-theta.
3. The carvedilol of claim **2** further characterized by PXRD peaks at about 5.8, 10.7, 11.1, 11.5, 13.1, 13.7, 16.8, 17.7, 18.5, and 23.0 ± 0.2 degrees two-theta.
4. The carvedilol of claim **3** characterized by a PXRD pattern substantially a depicted in Figure 1.
5. The carvedilol of claim **1** characterized by DSC peaks at about 74° C and 112° C.
6. The carvedilol of claim **5** characterized by a DSC thermogram substantially as depicted in Figure 3.
7. The carvedilol of claim **6** characterized by FTIR peaks at about 613, 740, 994, 1125, 1228, 1257, 1441, 1508, 1737, 2840, 3281, 3389, and 3470 cm^{-1}.
8. The carvedilol of claim **7** further characterized by FTIR peaks at about 720, 1100, 1286, 1454, 1589, 2911, and 2935 cm^{-1}.
9. The carvedilol of claim **8** characterized by a FTIR spectrum as substantially depicted in Figure 2.
10. Crystalline carvedilol Form VI.
11. A process for preparing the crystalline solid of carvedilol or a solvate thereof of claim **1** comprising the steps of:

    contacting carvedilol and ethyl acetate to form a solution, and

    cooling the solution whereby a precipitate is formed.
12. The process of claim **11** wherein the cooling step is performed under agitation.
13. The process of claim **11** wherein the temperature of the solution is reduced to about 40° C to about 55° C.
14. The process of claim **11** further comprising the steps of:

seeding the solution with carvedilol Form II to form a suspension,

cooling the suspension whereby a precipitate is formed.

15. The process of claim **14** wherein the temperature of the suspension is reduced to about 10° C.

16. The process of claim **15** wherein the cooling step is performed under agitation.

17. The crystalline solid of carvedilol or a solvate thereof prepared by the process of claim **11**.

18. A pharmaceutical composition comprising an effective amount of the crystalline solid of carvedilol or a solvate thereof of claim **1** and at least one pharmaceutically acceptable excipient.

19. A pharmaceutical dosage form comprising the pharmaceutical composition of claim **18**.

20. The pharmaceutical dosage form of claim **19** wherein the dosage form is an oral dosage form.

21. The pharmaceutical dosage form of claim **20** wherein the oral dosage form is a capsule or tablet.

22. A method of treating hypertension in a patient suffering from hypertension by administering to the patient a dosage form of claim **19**.

23. A method of treating congestive heart failure in a patient suffering from congestive heart failure by administering to the patient a dosage form of claim **19**.

24. A process for preparing a crystalline solid of carvedilol Form II comprising the steps of:

heating crystalline carvedilol of claim 1 until the crystalline carvedilol is dry,

mixing carvedilol Form II with the dry crystalline carvedilol, and

storing the mixture for a holding time sufficient to transform the dry crystalline carvedilol into Form II.

25. The process of claim **24**, wherein the crystalline carvedilol is heated to a temperature of from about 50° C to about 60° C.

26. The process of claim **25** wherein the heating step is performed under reduced pressure.

27. The process of claim **26** wherein the pressure is at about 30 mm Hg.